SCHEMBL16044787

SCHEMBL16044787

Cn1nc(-c2ccnc(F)c2)c2scc(-c3ccncc3)c2c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 3/20 0.38
ADORA2A P29274 2/20 0.36
GABRA1 P14867 3/20 0.36
GABRG2 P18507 3/20 0.36
GABRB3 P28472 3/20 0.36
GABRA3 P34903 3/20 0.36
GABRA2 P47869 3/20 0.36
GABRA5 P31644 2/20 0.36
NFATC1 O95644 1/20 0.35
DYRK1A Q13627 1/20 0.35
MAPK14 Q16539 2/20 0.34
CSNK1D P48730 2/20 0.34
CSNK1E P49674 2/20 0.34
MAPK13 O15264 1/20 0.34
MAPK12 P53778 1/20 0.34
MAPK11 Q15759 1/20 0.34
GRM1 Q13255 4/20 0.34
TSHR P16473 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL18759481 0.92 PDE10A (0.41) ADORA2BADORA2AGABRA1GABRG2GABRB3
SCHEMBL16044407 0.88 GABRA1 (0.40) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL16044197 0.88 GABRA1 (0.38) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL16046796 0.86 GRM1 (0.44) ADORA2BADORA2AGABRA1GABRG2GABRB3
SCHEMBL16044266 0.86 MAPK14 (0.50) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL16046501 0.86 MAPK14 (0.50) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL16045669 0.84 CYP2A6 (0.38) GABRA1GABRG2GABRB3GABRA3GABRA2
Trifluoroacetic Acid SCHEMBL18759462 0.82 PDE10A (0.40) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL16045415 0.82 KMT2A (0.46) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL16045348 0.82 KMT2A (0.46) GABRA1GABRG2GABRB3GABRA3GABRA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970328-B1 NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A ABBVIE DEUTSCHLAND (DE) 2017-04-26 EP claimed
US-9200005-B2 Inhibitor compounds of phosphodiesterase type 10A AbbVie Deutschland GmbH & Co. KG (DE) 2015-12-01 US claimed
US-20140275069-A1 Novel inhibitor compounds of phosphodiesterase type 10A AbbVie Deutschland GmbH & Co. KG (DE) 2014-09-18 US claimed
EP-2970328-B1 NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A ABBVIE DEUTSCHLAND (DE) 2017-04-26 EP disclosed
US-9200005-B2 Inhibitor compounds of phosphodiesterase type 10A AbbVie Deutschland GmbH & Co. KG (DE) 2015-12-01 US disclosed
US-20140275069-A1 Novel inhibitor compounds of phosphodiesterase type 10A AbbVie Deutschland GmbH & Co. KG (DE) 2014-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275069-A1 Novel inhibitor compounds of phosphodiesterase type 10A PDE5A, PDE3A, PDE3B ADORA2B 226/4885ADORA2A 355/4885GABRA1 2834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.